AFP and neoplasm: In multivariate analysis, ECOG performance statuses 1–2 (HR = 1.956, P = 0.004), tumor size >10 cm (HR = 1.597, P = 0.049), AFP >400 ng/mL (HR = 1.869, P = 0.008), discontinuation of sorafenib due to LD (HR = 6.142, P = 0.002) or concurrent PD and LD (HR = 2.661, P < 0.001), and PD within 4 months (HR = 5.164, P < 0.001) were independent factors associated with OS.